{"id":107,"date":"2025-12-07T17:56:31","date_gmt":"2025-12-07T17:56:31","guid":{"rendered":"https:\/\/blogs.cardiff.ac.uk\/karen-reed\/?p=107"},"modified":"2025-12-07T18:27:44","modified_gmt":"2025-12-07T18:27:44","slug":"diabetes-menopause-what-everyone-should-know-and-why-oestrogen-matters","status":"publish","type":"post","link":"https:\/\/blogs.cardiff.ac.uk\/karen-reed\/diabetes-menopause-what-everyone-should-know-and-why-oestrogen-matters\/","title":{"rendered":"Diabetes & Menopause: What Everyone Should Know (and Why Oestrogen Matters)"},"content":{"rendered":"
\"Infographic<\/figure>\n

It is Sunday 7th December as I write this, and given that last week, and next week, that is the last 2 weeks of teaching of 2025, I have been supporting Year 2 MBBCh students who are studying a diabetes case featuring a woman in her 60\u2019s, I had wanted to share a resource that explores the link between diabetes and menopause. However, time has run away from me, so the best I can do is a blog post on the topic. To see this come to fruition, rather than it remain as an unfinished item on the wish list in my head, I have used both the Elicit tool and Copilot, made available to me by Cardiff Uni, to help draft this text (and draw the image). My aim is to provide a scientifically sound overview, with references to peer-reviewed research (which I confess I have not read with my usual vigour and critique), that connects what students are learning to real-world physiology and clinical implications. Feedback and comments are welcomed, if constructive and polite.<\/p>\n

So why does menopause matter for diabetes risk?<\/strong><\/h4>\n

Menopause isn\u2019t only about hot flushes and sleep disruption; it\u2019s a metabolic turning point for many of us. One big question that I think it is important to ask is: does the drop in oestrogen change insulin sensitivity and raise the risk of type 2 diabetes (T2D)? <\/strong>The short answer appears to be YES. <\/strong><\/p>\n

Oestrogen is a key regulator of insulin action, and falling levels of oestrogen around menopause can tilt metabolism toward insulin resistance<\/em>.<\/p><\/blockquote>\n

The longer answer (with the accompanying evidence) is below.<\/p>\n

 <\/p>\n

The link between oestrogen and insulin.<\/strong><\/h4>\n

Oestrogen, especially 17\u03b2\u2011oestradiol (E2), supports how our bodies handle glucose. It does this through multiple receptors (ER\u03b1, ER\u03b2 and G\u2011protein\u2011coupled estrogen receptor, GPER), influencing pancreatic \u03b2\u2011cell function, glucose transporters such as GLUT4, hepatic glucose production, adipose tissue distribution, and inflammatory pathways that drive insulin resistance. In preclinical and translational work, oestrogen signalling via the ER\u03b1\/PI3K\/Akt pthway suppresses hepatic gluconeogenesis and improves insulin sensitivity, which helps keep fasting glucose down (Meyer\u2005et\u2005al.,\u20052011;\u2005Prossnitz\u2005&\u2005Barton,\u20052011;\u2005Yan\u2005et\u2005al.,\u20052019)<\/a>.<\/p>\n

As oestrogen levels decline during the menopause transition, insulin sensitivity and glucose tolerance can worsen<\/strong>, increasing T2D risk beyond what we\u2019d expect from ageing alone. Clinical reviews conclude that menopause is accompanied by central fat redistribution, reduced energy expenditure, and impairments in insulin secretion and sensitivity<\/strong>\u2014a combination that predisposes to T2D (Lambrinoudaki\u2005et\u2005al.,\u20052022;\u2005Paschou\u2005et\u2005al.,\u20052019)<\/a>.<\/p>\n

<\/h4>\n

Is it \u201cproven\u201d that oestrogen alters insulin sensitivity?<\/strong><\/h4>\n

YES! Both mechanistic and clinical evidence support this.<\/strong> Experimental studies show E2 improves insulin sensitivity and glucose metabolism; blocking or losing oestrogen signalling pushes the system the other way (Yan\u2005et\u2005al.,\u20052019)<\/a>.<\/p>\n

Clinically, the most rigorous measure of insulin action (the hyperinsulinaemic\u2013euglycaemic clamp) demonstrates a timing effect between estradiol administration after menopause and the effect on insulin action: short\u2011term transdermal oestradiol increased<\/em><\/strong> insulin\u2011mediated glucose disposal in women \u22646 years post\u2011menopause but decreased<\/em><\/strong> it in women \u226510 years post\u2011menopause. This \u201ctiming hypothesis\u201d suggests oestrogen\u2019s metabolic benefits are more likely when therapy is initiated closer to menopause, and may be blunted or reversed later (Pereira\u2005et\u2005al.,\u20052015)<\/a>.<\/p>\n

At a population level, large, randomised trials and meta\u2011analyses show that menopausal hormone therapy (MHT) reduces the incidence of Type 2 diabetes and improves glycaemic indices\u2014yet it\u2019s not licensed solely to prevent diabetes<\/strong> because benefits must be weighed against individual risks (Mauvais\u2011Jarvis\u2005et\u2005al.,\u20052017;\u2005Speksnijder\u2005et\u2005al.,\u20052023)<\/a>.<\/p>\n

<\/h4>\n

The take home messages from reviews of the trials.<\/strong><\/h4>\n